Vertex Pharmaceuticals (VRTX) Stock Price, News & Analysis

Vertex Pharmaceuticals logo
$536.45 +2.25 (+0.42%)
Closing price 04:00 PM Eastern
Extended Trading
$539.29 +2.84 (+0.53%)
As of 07:57 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Vertex Pharmaceuticals Stock (NASDAQ:VRTX)

Advanced

Key Stats

Today's Range
$531.38
▼
$542.76
50-Day Range
$485.22
▼
$558.88
52-Week Range
$412.27
▼
$568.67
Volume
1.29 million shs
Average Volume
1.56 million shs
Market Capitalization
$136.01 billion
P/E Ratio
31.41
Dividend Yield
N/A
Price Target
$596.44
Consensus Rating
Moderate Buy

Company Overview

Vertex Pharmaceuticals is a biotechnology company headquartered in Boston, Massachusetts. Founded in 1989, it develops medicines for serious diseases, with a long-standing focus on cystic fibrosis (CF).

Vertex’s CF treatments include medicines that target the underlying protein defect, such as Trikafta/Kaftrio, Alyftrek, Kalydeco, Orkambi and Symdeko/Symkevi. The company also markets Journavx, a non-opioid medicine for acute pain, and partnered with CRISPR Therapeutics to develop Casgevy, a gene-editing treatment for sickle cell disease and transfusion-dependent beta thalassemia.

Vertex serves patients in the United States and international markets, including Europe. Reshma Kewalramani has served as the company’s president and chief executive officer since 2020.

AI Generated. May Contain Errors.

Vertex Pharmaceuticals Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
69th Percentile Overall Score

VRTX MarketRank™: 
3.44913991602 of 5 stars

Vertex Pharmaceuticals scored higher than 69% of companies evaluated by MarketBeat, and ranked 657th out of 1,706 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Vertex Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.96, and is based on 1 strong buy rating, 25 buy ratings, 2 hold ratings, and no sell ratings.

  • Upside Potential

    Vertex Pharmaceuticals has a consensus price target of $596.44, representing about 11.2% upside from its current price of $536.45.

  • Amount of Analyst Coverage

    Vertex Pharmaceuticals has been the subject of 15 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

  • Read more about Vertex Pharmaceuticals' stock forecast and price target.
  • Earnings Growth

    Earnings for Vertex Pharmaceuticals are expected to grow by 11.30% in the coming year, from $16.10 to $17.92 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Vertex Pharmaceuticals is 31.41, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 25.91.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Vertex Pharmaceuticals is 31.41, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 33.58.

  • Price to Earnings Growth Ratio

    Vertex Pharmaceuticals has a PEG Ratio of 2.83. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Vertex Pharmaceuticals has a P/B Ratio of 6.51. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    1.90% of the float of Vertex Pharmaceuticals has been sold short.
  • Short Interest Ratio / Days to Cover

    Vertex Pharmaceuticals has a short interest ratio ("days to cover") of 3.38, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Vertex Pharmaceuticals has recently increased by 12.87%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Vertex Pharmaceuticals does not currently pay a dividend.

  • Dividend Growth

    Vertex Pharmaceuticals does not have a long track record of dividend growth.

  • News Sentiment

    Vertex Pharmaceuticals has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 22 news articles for Vertex Pharmaceuticals this week, compared to 9 articles on an average week.
  • Search Interest

    Only 10 people have searched for VRTX on MarketBeat in the last 30 days. This is a decrease of -66% compared to the previous 30 days.
  • MarketBeat Follows

    33 people have added Vertex Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 136% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Vertex Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $9,071,071.00 in company stock.

  • Percentage Held by Insiders

    0.20% of the stock of Vertex Pharmaceuticals is held by insiders.

  • Percentage Held by Institutions

    90.96% of the stock of Vertex Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Vertex Pharmaceuticals' insider trading history.
Receive VRTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vertex Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

VRTX Stock News Headlines

Pentagon magnet restrictions take effect January 1, 2027
A NASDAQ-listed company has signed a term sheet outlining a potential 75-year agreement with the U.S. Army. It would build and operate a rare earth processing facility on an active military base, with the Army receiving first right to production. The timing matters. New Pentagon restrictions on certain Chinese-origin rare earth magnets take effect January 1, 2027, while China controls more than 90% of global rare earth processing. The company's mine-to-magnet platform spans feedstock agreements, processing facilities, metallization technology, and downstream manufacturing, with initial commercial output targeted for 2027.tc pixel
See More Headlines

VRTX Stock Analysis - Frequently Asked Questions

Vertex Pharmaceuticals' stock was trading at $453.36 at the beginning of 2026. Since then, VRTX shares have increased by 18.3% and is now trading at $536.45.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) posted its quarterly earnings results on Monday, November, 2nd. The pharmaceutical company reported $4.76 EPS for the quarter, missing the consensus estimate of $4.82 by $0.06. The company's quarterly revenue was up 11.8% compared to the same quarter last year.
Read the conference call transcript
.

Vertex Pharmaceuticals subsidiaries include these companies: V2X, Semma Therapeutics, Exonics Therapeutics, Aurora Biosciences Corporation, The Vertex Foundation Inc., Torreyana Insurance Company Inc., Vertex Farmaceutica do Brasil LTDA, and others.

Vertex Pharmaceuticals' top institutional shareholders include State Street Corp (4.74%), First Trust Advisors LP (0.28%), Pictet Asset Management Holding SA (0.25%) and Sumitomo Mitsui Trust Group Inc. (0.23%). Insiders that own company stock include Reshma Kewalramani, Stuart A Arbuckle, Amit Sachdev, Ourania Tatsis, Bruce I Sachs, Charles F Wagner Jr, Jeffrey M Leiden, David Altshuler, Joy Liu, Edward Morrow Atkinson III, Carmen Bozic, Jonathan Biller, Duncan Mckechnie, Mark E Bunnage, Kristen Ambrose, Sangeeta N Bhatia and Nancy Thornberry.
View institutional ownership trends
.

Shares of VRTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Vertex Pharmaceuticals investors own include NVIDIA (NVDA), Tesla (TSLA), Advanced Micro Devices (AMD), Salesforce (CRM), Alibaba Group (BABA), Micron Technology (MU) and Netflix (NFLX).

Company Calendar

Last Earnings
11/02/2026
Today
11/18/2026
9th Annual Evercore ISI HealthCONx Conference
12/01/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:VRTX
CIK
875320
Employees
6,400
Year Founded
1989

Price Target and Rating

High Price Target
$725.00
Low Price Target
$442.00
Potential Upside/Downside
+11.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.96
Research Coverage
28 Analysts

Profitability

EPS (Trailing Twelve Months)
$15.54
Trailing P/E Ratio
31.41
Forward P/E Ratio
29.94
P/E Growth
2.83
Net Income
$3.95 billion
Net Margins
30.70%
Pretax Margin
36.74%
Return on Equity
21.98%
Return on Assets
15.50%

Debt

Debt-to-Equity Ratio
0.17
Current Ratio
2.34
Quick Ratio
1.89

Sales & Book Value

Annual Sales
$12.00 billion
Price / Sales
11.33
Cash Flow
$17.65 per share
Price / Cash Flow
30.39
Book Value
$82.46 per share
Price / Book
6.51

Miscellaneous

Outstanding Shares
253,540,000
Free Float
253,031,000
Market Cap
$136.01 billion
Optionable
Optionable
Beta
0.28

Social Links

Don't Wait for the OpenAI IPO Cover

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

This page (NASDAQ:VRTX) was last updated on 11/18/2026 by MarketBeat.com Staff.
From Our Partners